摘要
目的:观察吉西他滨联合希罗达治疗晚期胰腺癌的疗效和不良反应。方法:对50例晚期胰腺癌患者给予此方案化疗4个周期,按WHO标准评定疗效及不良反应,同时综合评估临床受益率指标:疼痛、体力状况及体重变化。结果:客观有效率为42.9%,中位生存时间为7.4个月,1年生存率为32%。主要不良反应为血液学毒性和脱发。结论:吉西他滨加希罗达是治疗晚期胰腺癌的一种安全有效的化疗方案,有较高的肿瘤缓解率,毒性较低,值得在临床上进一步推广应用。
Objective：To evaluate the efficacy and toxicity of combination therapy with gemcitabine and capecitabine in advanced pancreatic carcinoma.Method：50 patients was treated with this regimen for 4 cycles.The efficacy and side effect were evaluated according to the WHO criterion,and the indexes of CBR including ache,physical strength and body weight were also evaluated.Result：The objective response rate was 42.9%,the media survival time was 7.4 months,survival rate of one year was 53.8%.The main adverse reactions had hematologic toxicity and hair loss.Conclusion：Gemcitabine combined with capecitabine for treatment of advanced pancreatic cancer may obtain high response rate and comparatively low toxicity.This is a kind of effective and safe regimen of chemotherapy.May obtain high response rate and comparatively low toxicity.
出处
《河北医学》
CAS
2010年第6期700-703,共4页
Hebei Medicine
关键词
吉西他滨
希罗达
晚期胰腺癌
Gemcitabine
Capecitabine
Advanced pancreatic cancer
